Tirzepatide

1.Product name: Tirzepatide
2.Appearance:White powder
3.Molecular Formula: /
4.Molecular Weight:0
5.CAS No.: 1078-21-3
6.Purity: 99%
7.Test Method: HPLC
8.Payment method: TT, Western Union,Paypal,Pingpong,Xtransfer,ect.
9.Shelf Life: 2 years

Send Inquiry Chat Now

Description

Product Introduction

Tirzepatide is a new glucagon-like peptide-1 receptor (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP, aka: gastric inhibitory polypeptide) dual-receptor agonist, administered once a week. both GLP-1 and GIP belong to the enteroglucagon, which is a polypeptide secreted by the mucous membranes of the gastrointestinal tract of the human body. the former can bind with the receptor on the pancreatic islet cell and GLP-1 and GIP are both enteroglucagon, peptides secreted by the mucosa of the human gastrointestinal tract. The former can bind to the receptors on pancreatic islet cells and stimulate insulin secretion to produce glucose-lowering effects, as well as delaying gastric emptying and suppressing appetite, thus controlling body weight; the latter has the ability to inhibit the secretion of gastric acid, pepsin, stimulate insulin release, and inhibit gastric peristalsis and emptying, which complements the effects of the GLP-1 agonist. diabetes mellitus and represents a novel class of drugs for the treatment of type 2 diabetes mellitus.Translated with DeepL.com (free version)

Product Photo and action

Tirzepatide

Product Specification

Tirzepatide

Product Function

Tirzepatide shares a similar sequence to semaglutide, with the lys side chain of the sequence bearing a PEG modification, which is a functional group of the peptide, as well as the ability to increase the water solubility of the sequence.The primary physiological function of Tirzepatide is that of a dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor. It is being developed for the treatment of type 2 diabetes mellitus and has entered the clinical phase.Translated with DeepL.com (free version)

Safety
The safety profile of tilpeptide is similar to that of other enteroglucagon analogues. A Meta-analysis of seven randomised controlled trials showed that gastrointestinal reactions (e.g. nausea, diarrhoea and constipation) were significantly elevated with tilpeptide compared to placebo, but most were mild to moderate. Other adverse reactions, especially hypoglycaemia were not found to be significantly different between the two groups. However, due to the short time on the market, the actual safety remains to be demonstrated post-marketing.

Effectiveness in Glucose Reduction and Weight Loss
The SURPASS studies are a series of large clinical randomised controlled trials designed to assess the efficacy and safety of tilprotide in patients with type 2 diabetes mellitus (T2DM). Of these, the most exciting results were seen in SURPASS-2[1], a head-to-head comparison with simethicone, which compared the glucose-lowering efficacy of tilpeptide 5mg (n=470), 10mg (n=469), and 15mg (n=469) with simethicone 1mg (n=468). The results showed that compared to baseline HbA1c (8.3 per cent) levels, tilpeptide reduced subjects' HbA1c by an average of 2.0, 2.2 and 2.3 per cent, compared to an average of 1.9 per cent for simelglutide, and in terms of weight loss, compared to baseline body weight (207 lbs), tilpeptide resulted in an average weight loss of 17 lbs, 21 lbs and 25 lbs for the subjects, compared to 13 lbs for simelglutide. This trial showed that tilprotide demonstrated superior glucose reduction and weight loss compared to semeglutide. Another large study enrolled 2,539 adults with at least one obesity complication (excluding diabetes mellitus) and a body mass index (BMI) of ≥30kg/m2 or ≥27kg/m2. All subjects were randomised in equal proportions to the tilprotectin 5mg, 10mg, and 15mg versus placebo groups, and the results showed that, at 72 weeks, the groups had a reduction in body weight of 16.1kg, 22.2kg, 23.6kg, and 2.4kg respectively [2]. The weight loss effect of tilpeptide is comparable to weight loss surgery.

Product Application

Tilpeptide reduces food intake, lowers body weight and lowers adiposity by decreasing caloric intake and regulating appetite. In addition, tilpeptide has been shown to regulate lipid utilisation. In May 2022, tilpeptide was approved by the U.S. FDA for improving glycaemic control (on the basis of dietary control and exercise) in adults with type 2 diabetes, and in November 2023, the product was approved by the FDA for the long-term management of weight (on the basis of a low-calorie diet and increased physical activity) in obese (BMI ≥ 30 kg/m2 ) or overweight adults with at least one comorbidity (BMI ≥ 27 kg/m2 ). activity).

Tirzepatide